Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project.

Marchetti E, Mazarin-Diop V, Chaumont J, Martellet L, Makadi MF, Viviani S, Kulkarni PS, Preziosi MP.

Vaccine. 2012 Nov 6;30(48):6859-63. doi: 10.1016/j.vaccine.2012.09.008.

PMID:
22989686
2.

The Meningitis Vaccine Project.

LaForce FM, Konde K, Viviani S, Préziosi MP.

Vaccine. 2007 Sep 3;25 Suppl 1:A97-100.

PMID:
17521780
3.

Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).

Frasch CE, Preziosi MP, LaForce FM.

Hum Vaccin Immunother. 2012 Jun;8(6):715-24. doi: 10.4161/hv.19619. Review.

PMID:
22495119
4.

From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.

Aguado MT, Jodar L, Granoff D, Rabinovich R, Ceccarini C, Perkin GW.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S391-5. doi: 10.1093/cid/civ593. Review.

5.

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.

Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, Lingani C, Preziosi MP, Zuber PL, Perea W, Hugonnet S, Dellepiane de Rey Tolve N, Tevi-Benissan C, Clark TA, Mayer LW, Novak R, Messonier NE, Berlier M, Toboe D, Nshimirimana D, Mihigo R, Aguado T, Diomandé F, Kristiansen PA, Caugant DA, Laforce FM.

Vaccine. 2012 May 30;30 Suppl 2:B40-5. doi: 10.1016/j.vaccine.2011.12.073. Review.

PMID:
22607898
6.
7.

Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.

Mueller JE, Borrow R, Gessner BD.

Expert Rev Vaccines. 2006 Jun;5(3):319-36. Review.

PMID:
16827617
8.

Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.

Soriano-Gabarró M, Rosenstein N, LaForce FM.

J Health Popul Nutr. 2004 Sep;22(3):275-85.

PMID:
15609780
9.

Technical Development of a New Meningococcal Conjugate Vaccine.

Frasch CE, Kapre SV, Lee CH, Préaud JM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S404-9. doi: 10.1093/cid/civ595. Review.

10.

Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.

Hirve S, Bavdekar A, Pandit A, Juvekar S, Patil M, Preziosi MP, Tang Y, Marchetti E, Martellet L, Findlow H, Elie C, Parulekar V, Plikaytis B, Borrow R, Carlone G, Kulkarni PS, Goel A, Suresh K, Beri S, Kapre S, Jadhav S, Preaud JM, Viviani S, LaForce FM.

Vaccine. 2012 Oct 5;30(45):6456-60. doi: 10.1016/j.vaccine.2012.08.004.

PMID:
22898557
11.

Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2012 Dec 21;61(50):1025-8.

12.

Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.

Okoko BJ, Idoko OT, Adegbola RA.

Vaccine. 2009 Mar 23;27(14):2023-9. doi: 10.1016/j.vaccine.2008.11.092. Review.

PMID:
19095025
13.

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.

Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S.

Vaccine. 2009 Jun 24;27 Suppl 2:B13-9. doi: 10.1016/j.vaccine.2009.04.062. Review.

PMID:
19477559
14.

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa.

Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, Bouveret N, LaForce FM, Frasch CE.

Vaccine. 2009 Jan 29;27(5):726-32. doi: 10.1016/j.vaccine.2008.11.065.

PMID:
19063929
15.

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.

Idoko OT, Diallo A, Sow SO, Hodgson A, Akinsola A, Diarra B, Haidara FC, Ansah PO, Kampmann B, Bouma E, Preziosi MP, Enwere GC.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S416-21. doi: 10.1093/cid/civ596. Review.

16.

[Critical review of control strategies for meningococcal meningitis epidemics in Sub-Saharan Africa].

Chippaux JP, Debois H, Saliou P.

Bull Soc Pathol Exot. 2002 Mar;95(1):37-44. Review. French.

PMID:
12012963
17.

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.

Djingarey MH, Diomandé FV, Barry R, Kandolo D, Shirehwa F, Lingani C, Novak RT, Tevi-Benissan C, Perea W, Preziosi MP, LaForce FM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S434-41. doi: 10.1093/cid/civ551. Review.

18.

The Evolution of the Meningitis Vaccine Project.

Tiffay K, Jodar L, Kieny MP, Socquet M, LaForce FM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S396-403. doi: 10.1093/cid/civ594. Review.

19.

Control of meningococcal meningitis outbreaks in sub-Saharan Africa.

Chippaux JP.

J Infect Dev Ctries. 2008 Oct 1;2(5):335-45. Review.

20.

Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010.

Chaibou MS, Bako H, Salisou L, Yaméogo TM, Sambo M, Kim SH, Djingarey MH, Zuber PL, Perea WA, Pezzoli L.

Vaccine. 2012 Jul 27;30(35):5229-34. doi: 10.1016/j.vaccine.2012.06.006.

PMID:
22709955
Items per page

Supplemental Content

Support Center